my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
28-06-2012: ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.
PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other cells and its primary function is the attraction of neutrophils to sites of acute and chronic inflammation. PA401 acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is a hallmark of many respiratory diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
In an exciting twist, two companies have been announced as winners of EuropaBio’s Most Innovative Biotech SME Award 2012. Commission Vice President Tajani who presented the award, during the event hosted by Dr. Kay Swinburne MEP at the European Parliament, named both Austrian healthcare bi ... more
ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease
ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and othe ... more
ProtAffin AG announces preclinical data in Multiple Sclerosis for MCP-1 decoy program
ProtAffin AG announced preclinical data on its MCP-1 decoy program in a model of multiple sclerosis at the ECTRIMS/ACTRIMS conference.The Company presented a poster on its MCP-1 decoy program at the Immunomodulation session at the ECTRIMS/ACTRIMS conference, which is the 5th Joint Triennial ... more
ProtAffin Biotechnologie AG is a pre-clinical biotechnology company based in Graz, Austria. We focus on developing novel biotechnology products for acute and chronic inflammatory diseases. We are leaders in the field of protein-glycan interactions, which are increasingly recognised as driv ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
